Pediatrix Medical Group delivered strong Q3 results, surpassing internal expectations. The company benefited from favorable reimbursement dynamics and higher patient acuity, resulting in significant growth in same-unit revenue and profitability.
Revenue reached $492.9 million, down from $511.2 million YoY due to practice dispositions, but same-unit revenue grew 8.0%
Net income jumped to $71.7 million, compared to $19.4 million in the prior-year quarter
Adjusted EPS increased to $0.67 from $0.44 a year earlier
Raised full-year 2025 Adjusted EBITDA guidance to a range of $270 million to $290 million
Pediatrix raised its full-year 2025 Adjusted EBITDA forecast to a range of $270–$290 million, driven by better-than-expected performance in Q3.
Analyze how earnings announcements historically affect stock price performance